Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial.

Abstract

Simvastatin (MK 733), a new competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, given in daily doses of 20 mg and 40 mg for 104 weeks, has been shown to lower the serum total cholesterol and low density lipoprotein cholesterol level by more than 30% and the serum apoprotein B level by 20% in 19 adult patients with heterozygous familial hypercholesterolemia. A slight but non-significant increase of high density lipoprotein cholesterol levels was shown throughout the trial with significant elevation of the serum apoproteins AI and AII only observed at week 52. Mild and transient clinical or biochemical (increases of creatine phosphokinase and transaminases) side effects, observed in some patients, did not necessitate the withdrawal of the medication. Full ophthalmological examinations did not reveal ocular disturbances, particularly no apparent increase of lens opacities, during the trial. Simvastatin seems to be an effective and safe drug as monotherapy in the treatment of heterozygous familial hypercholesterolemia.

Statistics

0200400'93'96'99'02'05'08'11'14'17
Citations per Year

303 Citations

Semantic Scholar estimates that this publication has 303 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Leclercq1989Simvastatin7, title={Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial.}, author={Val{\'e}rie Leclercq and C M Harvengt}, journal={International journal of clinical pharmacology, therapy, and toxicology}, year={1989}, volume={27 2}, pages={76-81} }